{"id":"NCT02792218","sponsor":"Novartis Pharmaceuticals","briefTitle":"Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis","officialTitle":"A Randomized, Double-blind, Double-dummy, Parallel-group Study Comparing the Efficacy and Safety of Ofatumumab Versus Teriflunomide in Patients With Relapsing Multiple Sclerosis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-09-20","primaryCompletion":"2019-07-05","completion":"2020-07-20","firstPosted":"2016-06-07","resultsPosted":"2020-10-19","lastUpdate":"2021-10-01"},"enrollment":930,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Relapsing Multiple Sclerosis"],"interventions":[{"type":"DRUG","name":"Ofatumumab subcutaneous injection","otherNames":[]},{"type":"DRUG","name":"Teriflunomide-matching placebo capsules","otherNames":[]},{"type":"DRUG","name":"Teriflunomide capsule","otherNames":[]},{"type":"DRUG","name":"Matching placebo of ofatumumab subcutaneous injections","otherNames":[]}],"arms":[{"label":"OMB 20 mg","type":"EXPERIMENTAL"},{"label":"TER 14 mg","type":"ACTIVE_COMPARATOR"}],"summary":"To compare the efficacy and safety of ofatumumab administered subcutaneously (sc) every 4 weeks versus teriflunomide administered orally once daily in patients with relapsing multiple sclerosis","primaryOutcome":{"measure":"Annualized Relapse Rate (ARR)","timeFrame":"Baseline up to 2.5 years","effectByArm":[{"arm":"OMB 20 mg","deltaMin":0.11,"sd":null},{"arm":"TER 14 mg","deltaMin":0.22,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":166,"countries":["United States","Argentina","Australia","Belgium","Bulgaria","Canada","Croatia","Czechia","Denmark","Estonia","France","Germany","Greece","Hungary","India","Israel","Italy","Mexico","Netherlands","Poland","Puerto Rico","Russia","Slovakia","Spain","Sweden","Switzerland","Thailand","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":["39018512","37606897","35266417","32757523"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":51,"n":465},"commonTop":["Nasopharyngitis","Injection related reaction","Upper respiratory tract infection","Headache","Alopecia"]}}